Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 May 15.

Published in final edited form as: Clin Cancer Res. 2021 Sep 13;27(22):6174–6183. doi: 10.1158/1078-0432.CCR-21-0987

Table 2.

Association of OX40L positivity with clinicopathologic variables. Statistical analysis by Pearson Chi-Square test.

Variable	COHORT 1 (N=280)			COHORT 2 (N=207)

	OX40L-positive	OX40L-negative	p-value	OX40L-positive	OX40L-negative	p-value
	25 (9%)	255 (91%)		29 (14%)	178 (86%)
Age
≤ 70	16 (10%)	152 (90%)	0.719	23 (15%)	127 (85%)	0.420
> 70	9 (8%)	100 (92%)	0.719	4 (10%)	35 (90%)	0.420
Gender
Male	12 (10%)	107 (90%)	0.605	22 (13%)	142 (87%)	0.846
Female	13 (8%)	144 (92%)	0.605	3 (12%)	22 (88%)	0.846
Stage
Stage I-II	21 (10%)	188 (90%)	0.373	14 (13%)	97 (87%)	0.740
Stage III-IV	4 (6%)	59 (94%)	0.373	11 (14%)	66 (86%)	0.740
Histology
ADC	15 (9%)	153 (91%)	0.023	11 (15%)	61 (85%)	0.309
SCC	8 (15%)	45 (85%)		13 (14%)	78 (86%)
Others	0 (0%)	49 (100%)		1 (4%)	25 (96%)
Smoking status
Non/former smoker	9 (6%)	132 (94%)	0.077	1 (6%)	17 (94%)	0.300
Smoker	16 (13%)	110 (87%)	0.077	21 (14%)	125 (86%)	0.300